FDA issues Complete Response Letter for CTx-1301; no safety or efficacy concerns

Cingulate received an FDA Complete Response Letter for its ADHD drug CTx-1301 with only Chemistry, Manufacturing and Controls (CMC) information requests and no clinical safety or efficacy concerns identified. The company has $30 million in cash and plans to promptly resubmit with the requested information.